Agency Information Collection Activities; Proposed Collection; Comment Request; Quantitative Research on Front of Package Labeling on Packaged Foods, 5005-5007 [2023-01551]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 17 / Thursday, January 26, 2023 / Notices
By direction of the Commission.
April J. Tabor,
Secretary.
[FR Doc. 2023–01533 Filed 1–25–23; 8:45 am]
BILLING CODE 6750–01–P
GENERAL SERVICES
ADMINISTRATION
[OMB Control No. 3090–0310; Docket No.
2022–0001; Sequence No. 17]
Submission for OMB Review;
Nondiscrimination in Federal Financial
Assistance Programs, GSA Form 3702
Office of Civil Rights, General
Services Administration (GSA).
ACTION: Notice of request for comments
regarding an existing OMB clearance.
AGENCY:
Under the provisions of the
Paperwork Reduction Act, the
Regulatory Secretariat Division will be
submitting to the Office of Management
and Budget (OMB) a request to review
and approve an existing information
collection requirement regarding OMB
Control No: 3090–0310;
Nondiscrimination in Federal Financial
Assistance Programs, GSA 3702. This
information is needed to facilitate
nondiscrimination in GSA’s Federal
Financial Assistance Programs,
consistent with Federal civil rights laws
and regulations that apply to recipients
of Federal financial assistance.
DATES: Submit comments on or before:
February 27, 2023.
ADDRESSES: Written comments and
recommendations for this information
collection should be sent within 30 days
of publication of this notice to
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
Review—Open for Public Comments’’;
or by using the search function.
FOR FURTHER INFORMATION CONTACT:
Stephanie Stoltzfus Treier, Deputy
Associate Administrator, Office of Civil
Rights, at telephone 202–501–0767 or
via email to civilrights@gsa.gov.
SUPPLEMENTARY INFORMATION:
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
A. Purpose
GSA has mission responsibilities
related to monitoring and enforcing
compliance with Federal civil rights
laws and regulations that apply to
Federal financial assistance programs
administered by GSA. Specifically,
those laws provide that no person on
the ground of race, color, national
origin, disability, sex or age shall be
excluded from participation in, be
denied the benefits of, or be otherwise
subjected to discrimination under any
VerDate Sep<11>2014
17:17 Jan 25, 2023
Jkt 259001
program in connection with which
Federal financial assistance is extended
under laws administered in whole, or in
part, by GSA.
These mission responsibilities
generate the requirement to request and
obtain certain data from recipients of
Federal surplus property for the purpose
of determining compliance, such as the
number of individuals that speak nonEnglish languages encountered by the
recipient’s program(s) and how the
recipient is addressing meaningful
access for individuals that are Limited
English Proficient; whether the
recipients provide disability access in
compliance with applicable laws and
standards; whether there has been
complaints or lawsuits filed against the
recipient based on prohibited
discrimination; whether there has been
any findings of discrimination; and
whether the recipient’s facilities are
accessible to qualified individuals with
disabilities.
B. Annual Reporting Burden
Respondents: 1,200.
Responses per Respondent: 1.
Total Responses: 1,200.
Hours per Response: 2.
Total Burden Hours: 2,400.
C. Public Comments
A 60-day notice was published in the
Federal Register at 87 FR 70818 on
November 21, 2022. No comments were
received.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the GSA Regulatory Secretariat Division
by calling 202–501–4755 or emailing
GSARegSec@gsa.gov. Please cite OMB
Control No. 3090–0310,
Nondiscrimination in Federal Financial
Assistance Programs, GSA 3702, in all
correspondence.
Beth Anne Killoran,
Deputy Chief Information Officer.
[FR Doc. 2023–01550 Filed 1–25–23; 8:45 am]
BILLING CODE 6820–34–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–0155]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Quantitative
Research on Front of Package
Labeling on Packaged Foods
AGENCY:
Food and Drug Administration,
HHS.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
ACTION:
5005
Notice.
The Food and Drug
Administration (FDA or we) is
announcing an opportunity for public
comment on a proposed collection of
information. Under the Paperwork
Reduction Act of 1995 (PRA), Federal
Agencies are required to publish notice
in the Federal Register concerning each
proposed collection of information and
to allow 60 days for public comment in
response to the notice. This notice
invites comments on an information
collection associated with a study
entitled ‘‘Quantitative Research on
Front of Package Labeling on Packaged
Foods.’’
SUMMARY:
Either electronic or written
comments on the collection of
information must be submitted by
March 27, 2023.
DATES:
You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. The https://
www.regulations.gov electronic filing
system will accept comments until
11:59 p.m. Eastern Time at the end of
March 27, 2023. Comments received by
mail/hand delivery/courier (for written/
paper submissions) will be considered
timely if they are received on or before
that date.
ADDRESSES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
E:\FR\FM\26JAN1.SGM
26JAN1
5006
Federal Register / Vol. 88, No. 17 / Thursday, January 26, 2023 / Notices
lotter on DSK11XQN23PROD with NOTICES1
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2023–N–0155 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request;
Quantitative Research on Front of
Package Labeling on Packaged Foods.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ We
will review this copy, including the
claimed confidential information, in our
consideration of comments. The second
copy, which will have the claimed
confidential information redacted/
blacked out, will be available for public
viewing and posted on https://
www.regulations.gov. Submit both
copies to the Dockets Management Staff.
If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
VerDate Sep<11>2014
17:17 Jan 25, 2023
Jkt 259001
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10 a.m.–12 p.m.,
11601 Landsdown St., North Bethesda,
MD 20852, 301–796–5733, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3521), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal Agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Quantitative Research on Front of
Package Labeling on Packaged Foods
OMB Control Number 0910–NEW
The United States continues to face an
epidemic of diet-related chronic
diseases, many of which are
experienced disproportionately by racial
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
and ethnic minority groups, those with
lower socioeconomic status, and those
living in rural areas.1 To help address
this problem, FDA has continued to
prioritize its nutrition activities 2 to help
empower consumers with nutrition
information to make healthier choices
more easily and encourage industry
innovation by providing flexibility to
facilitate the production of healthier
foods. FDA is focused on: (1) creating a
healthier food supply for all; (2)
establishing a healthy start to set the
foundation for a long, healthy life; and
(3) empowering consumers through
informative labeling and tailored
education.3
FDA is exploring the development of
a front of package system to help
consumers interpret the nutrient
information on food products. Front of
Package (FOP) labeling is intended to
complement the Nutrition Facts label by
giving consumers a simple aid to
provide additional context for making
healthy food selections. As part of our
food-labeling efforts, we are exploring
the establishment of a standardized,
science-based FOP scheme that helps
consumers, particularly those with
lower nutrition literacy, quickly and
easily identify foods that are part of a
healthy eating pattern.
The increased attention in recent
years to FOP, and the experiences of
countries that have adopted FOP
labeling suggests that FOP labeling may
aid nutrition comprehension and the
ability to make healthier choices,
especially for those with lower nutrition
literacy. FOP schemes adopted in
countries throughout the world include
both mandatory and voluntary labeling
schemes and include non-interpretative,
interpretative, nutrient specific, and
summary schemes.
In 2022, FDA conducted a review of
the literature on FOP nutrition-related
labels and conducted a set of focus
groups to test FOP concepts and draft
FOP schemes (see Docket No. FDA–
2023–N–0155 for the literature review).
These focus group results provided
insights into the varying ways that
consumers interpret FOP nutrition
information. As part of our efforts to
promote public health, we intend to
conduct an experimental study,
informed by results of the focus group
testing, to further explore consumer
responses to various FOP schemes. In
the experimental study, we will test a
smaller subset of FOP schemes from the
1 https://www.cdc.gov/obesity/.
2 https://www.fda.gov/food/food-labelingnutrition/fdas-nutrition-initiatives.
3 https://www.whitehouse.gov/wp-content/
uploads/2022/09/White-House-National-Strategyon-Hunger-Nutrition-and-Health-FINAL.pdf.
E:\FR\FM\26JAN1.SGM
26JAN1
Federal Register / Vol. 88, No. 17 / Thursday, January 26, 2023 / Notices
focus group testing, with additional
variations informed by, among other
things, focus group results (see https://
www.reginfo.gov/public/do/PRAViewIC?
ref_nbr=202008-0910-021&icID=253321
for information about FDA’s front-ofpack focus groups, including graphic
FOP schemes tested). The study will be
a controlled, randomized experiment
that will use a 15-minute web-based
questionnaire to collect information
from 3,000 U.S. adult members of an
online consumer panel maintained by a
contractor. The sample will be balanced
to reflect the U.S. Census on gender,
education, age, and ethnicity/race. A
measure of nutrition literacy will also be
used to balance the sample to ensure a
variety of literacy levels for each
condition.
Conditions for the study will be: (1)
a set of draft FOP schemes, including
‘‘no-scheme’’ controls; (2) three types of
mock food products (i.e., a breakfast
cereal, a frozen meal, and a canned
soup); and (3) a ‘‘no-information’’
condition where no explanation of the
FOP scheme is provided. Each
participant will be randomly assigned to
a condition, which will include viewing
a label image and responding to various
measures of the label’s effectiveness.
Some assignments may include making
a choice between two label images.
Product perceptions (e.g., healthfulness
and contribution to a healthy diet), label
perceptions (e.g., believability,
trustworthiness, and effects
perceptions), and purchase/choice
questions will constitute the measures
of response in the experiment. The
5007
instrument will also collect information
from participants about their history of
purchasing or consuming similar
products, nutrition knowledge, dietary
interests, motivation regarding label use,
health status, and demographic
characteristics.
The studies are part of our continuing
effort to help enable consumers to make
informed dietary choices and construct
healthful diets. We intend to use the
results to inform our continued
exploration of an FOP labeling scheme.
We will not use the results to develop
population estimates.
Description of Respondents:
Respondents to this collection of
information include members of the
general public.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Activity
Number of
responses per
respondent
Total annual
responses
Total hours
Experiment Pretest 1 ...................................................
Experiment Pretest 2 ...................................................
Experiment ...................................................................
180
25
3,000
1
1
1
180
25
3,000
0.25 (15 minutes) ..
0.25 (15 minutes) ..
0.25 (15 minutes) ..
45
6
750
Total ......................................................................
........................
........................
........................
................................
801
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: January 23, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
Operations, Food and Drug
Administration, 3 White Flint North,
11601 Landsdown Street, North
Bethesda, MD 20852, 240–402–3156.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2023–01551 Filed 1–25–23; 8:45 am]
BILLING CODE 4164–01–P
I. Introduction
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Statement of Organization, Functions,
and Delegations of Authority
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA), Office of
Operations (OO), Office of Talent
Solutions (OTS) has modified its
structure, and the Office of FDA
Commissioned Corps (OFCC) was
established. These new organizational
structures were approved by the Deputy
Secretary of Health and Human Services
on September, 26, 2022, and effective on
November, 2, 2022.
FOR FURTHER INFORMATION CONTACT:
Tiffany Branch, Associate Director for
Management, Office of Enterprise
Management Services, Office of
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
Average burden
per response
VerDate Sep<11>2014
17:17 Jan 25, 2023
Jkt 259001
Part D, Chapter D–B, (Food and Drug
Administration), the Statement of
Organization, Functions and
Delegations of Authority for the
Department of Health and Human
Services (35 FR 3685, February 25,
1970, 60 FR 56606, November 9, 1995,
64 FR 36361, July 6, 1999, 72 FR 50112,
August 30, 2007, 74 FR 41713, August
18, 2009, 76 FR 45270, July 28, 2011,
and 84 FR 22854, May 20, 2019) is
amended to reflect the reorganization of
the OO, OTS and establishment of OO,
OFCC.
This reorganization established the
OO, OFCC. In the OTS immediate office
realigned the Commissioned Corps Staff
(CCS) functions and resources to OO,
OFCC; established the Business
Operations Staff; retitled the Policy and
Accountability Staff to Policy, Programs,
and Accountability Staff; and abolished
the CCS.
In the Division of Talent Services, I
(DTS I) retitled the division to Division
of Talent Solutions I (DTS I); retitled the
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
CDER Branch 1 to Recruitment and
Staffing Branch 1; retitled the CDER
Branch 2 to Recruitment and Staffing
Branch 2; retitled the CDER Branch 3 to
Recruitment and Staffing Branch 3
(RSB3); established the Recruitment and
Staffing Branch 4; and established the
Special Pay and Hiring Branch.
In the Division of Talent Services II
(DTS II) retitled the division to Division
of Talent Solutions II (DTS II); retitled
the CFSAN and CVM Branch to
Recruitment and Staffing Branch 5;
retitled OC and NCTR Branch to
Recruitment and Staffing Branch 6;
retitled the OO Branch to Recruitment
and Staffing Branch 7; established the
Classification Branch 1; and established
the Classification Branch 2.
In the Division of Talent Services III
(DTS III) retitled the division to Division
of Talent Solutions III (DTS III);
realigned the CBER Branch functions
and resources to DTS I/RSB3; realigned
the CDRH Branch functions and
resources to DTS II and retitled as
Recruitment and Staffing Branch 8;
realigned the CTP Branch functions and
resources to DTS II and retitled as
Recruitment and Staffing Branch 9;
established the OTS/DTS III/Data
Quality Branch 2; established the Data
E:\FR\FM\26JAN1.SGM
26JAN1
]]>Agencies
[Federal Register Volume 88, Number 17 (Thursday, January 26, 2023)]
[Notices]
[Pages 5005-5007]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-01551]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-N-0155]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Quantitative Research on Front of Package Labeling on
Packaged Foods
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing an
opportunity for public comment on a proposed collection of information.
Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are
required to publish notice in the Federal Register concerning each
proposed collection of information and to allow 60 days for public
comment in response to the notice. This notice invites comments on an
information collection associated with a study entitled ``Quantitative
Research on Front of Package Labeling on Packaged Foods.''
DATES: Either electronic or written comments on the collection of
information must be submitted by March 27, 2023.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of March 27, 2023. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are received on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
[[Page 5006]]
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2023-N-0155 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; Quantitative Research on Front of
Package Labeling on Packaged Foods.'' Received comments, those filed in
a timely manner (see ADDRESSES), will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at https://www.regulations.gov or at the Dockets Management
Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' We will review
this copy, including the claimed confidential information, in our
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information to be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify this information as ``confidential.''
Any information marked as ``confidential'' will not be disclosed except
in accordance with 21 CFR 10.20 and other applicable disclosure law.
For more information about FDA's posting of comments to public dockets,
see 80 FR 56469, September 18, 2015, or access the information at:
https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations,
Food and Drug Administration, Three White Flint North, 10 a.m.-12 p.m.,
11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733,
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3521), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes requests or requirements that members of the
public submit reports, keep records, or provide information to a third
party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Quantitative Research on Front of Package Labeling on Packaged Foods
OMB Control Number 0910-NEW
The United States continues to face an epidemic of diet-related
chronic diseases, many of which are experienced disproportionately by
racial and ethnic minority groups, those with lower socioeconomic
status, and those living in rural areas.\1\ To help address this
problem, FDA has continued to prioritize its nutrition activities \2\
to help empower consumers with nutrition information to make healthier
choices more easily and encourage industry innovation by providing
flexibility to facilitate the production of healthier foods. FDA is
focused on: (1) creating a healthier food supply for all; (2)
establishing a healthy start to set the foundation for a long, healthy
life; and (3) empowering consumers through informative labeling and
tailored education.\3\
---------------------------------------------------------------------------
\1\ https://www.cdc.gov/obesity/.
\2\ https://www.fda.gov/food/food-labeling-nutrition/fdas-nutrition-initiatives.
\3\ https://www.whitehouse.gov/wp-content/uploads/2022/09/White-House-National-Strategy-on-Hunger-Nutrition-and-Health-FINAL.pdf.
---------------------------------------------------------------------------
FDA is exploring the development of a front of package system to
help consumers interpret the nutrient information on food products.
Front of Package (FOP) labeling is intended to complement the Nutrition
Facts label by giving consumers a simple aid to provide additional
context for making healthy food selections. As part of our food-
labeling efforts, we are exploring the establishment of a standardized,
science-based FOP scheme that helps consumers, particularly those with
lower nutrition literacy, quickly and easily identify foods that are
part of a healthy eating pattern.
The increased attention in recent years to FOP, and the experiences
of countries that have adopted FOP labeling suggests that FOP labeling
may aid nutrition comprehension and the ability to make healthier
choices, especially for those with lower nutrition literacy. FOP
schemes adopted in countries throughout the world include both
mandatory and voluntary labeling schemes and include non-
interpretative, interpretative, nutrient specific, and summary schemes.
In 2022, FDA conducted a review of the literature on FOP nutrition-
related labels and conducted a set of focus groups to test FOP concepts
and draft FOP schemes (see Docket No. FDA-2023-N-0155 for the
literature review). These focus group results provided insights into
the varying ways that consumers interpret FOP nutrition information. As
part of our efforts to promote public health, we intend to conduct an
experimental study, informed by results of the focus group testing, to
further explore consumer responses to various FOP schemes. In the
experimental study, we will test a smaller subset of FOP schemes from
the
[[Page 5007]]
focus group testing, with additional variations informed by, among
other things, focus group results (see https://www.reginfo.gov/public/do/PRAViewIC?ref_nbr=202008-0910-021&icID=253321 for information about
FDA's front-of-pack focus groups, including graphic FOP schemes
tested). The study will be a controlled, randomized experiment that
will use a 15-minute web-based questionnaire to collect information
from 3,000 U.S. adult members of an online consumer panel maintained by
a contractor. The sample will be balanced to reflect the U.S. Census on
gender, education, age, and ethnicity/race. A measure of nutrition
literacy will also be used to balance the sample to ensure a variety of
literacy levels for each condition.
Conditions for the study will be: (1) a set of draft FOP schemes,
including ``no-scheme'' controls; (2) three types of mock food products
(i.e., a breakfast cereal, a frozen meal, and a canned soup); and (3) a
``no-information'' condition where no explanation of the FOP scheme is
provided. Each participant will be randomly assigned to a condition,
which will include viewing a label image and responding to various
measures of the label's effectiveness. Some assignments may include
making a choice between two label images. Product perceptions (e.g.,
healthfulness and contribution to a healthy diet), label perceptions
(e.g., believability, trustworthiness, and effects perceptions), and
purchase/choice questions will constitute the measures of response in
the experiment. The instrument will also collect information from
participants about their history of purchasing or consuming similar
products, nutrition knowledge, dietary interests, motivation regarding
label use, health status, and demographic characteristics.
The studies are part of our continuing effort to help enable
consumers to make informed dietary choices and construct healthful
diets. We intend to use the results to inform our continued exploration
of an FOP labeling scheme. We will not use the results to develop
population estimates.
Description of Respondents: Respondents to this collection of
information include members of the general public.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden per response Total hours
respondents respondent responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
Experiment Pretest 1......................... 180 1 180 0.25 (15 minutes)........................ 45
Experiment Pretest 2......................... 25 1 25 0.25 (15 minutes)........................ 6
Experiment................................... 3,000 1 3,000 0.25 (15 minutes)........................ 750
----------------------------------------------------------------------------------------------------------
Total.................................... .............. .............. .............. ......................................... 801
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: January 23, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-01551 Filed 1-25-23; 8:45 am]
BILLING CODE 4164-01-P
